We are live on ! Find out more
BIS icon

ProShares UltraShort NASDAQ Biotechnology
BIS

4 hedge funds and large institutions have $542K invested in ProShares UltraShort NASDAQ Biotechnology in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

77% more capital inflows, than outflows

Capital inflows: $204K | Capital outflows: $115K

3.47% more ownership

Funds ownership: 20.75% → 24.22% (+3.5%)

20% less funds holding

Funds holding: 5 → 4 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
4
Holders Change
-1
Holders Change %
-20%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Csenge Advisory Group
Csenge Advisory Group
Florida
+$185K
2
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$18.8K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$112K
2
UBS Group
UBS Group
Switzerland
-$3.22K
3
Morgan Stanley
Morgan Stanley
New York
-$47

BIS Hedge Fund Activity: Q3 2025 in Review

4 of the 7,657 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q3 2025, worth a combined $542K — down 14% from $629K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of BIS and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.

The largest buyer was Csenge Advisory Group, opening a new position worth an estimated $185K. The largest seller was Susquehanna International Group, cutting an estimated $112K.

  • 4 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q3 2025, down from 5 in Q2 2025.
  • Funds reported $542K of ProShares UltraShort NASDAQ Biotechnology stock for Q3 2025, down 14% quarter-over-quarter.
  • 1 fund opened new ProShares UltraShort NASDAQ Biotechnology positions in Q3 2025 and 2 closed out, a net change of -1 holder.
  • The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q3 2025 was Csenge Advisory Group, an estimated $185K added.
  • The largest ProShares UltraShort NASDAQ Biotechnology seller in Q3 2025 was Susquehanna International Group, an estimated $112K sold.

Based on aggregated 13F filings for Q3 2025.